Iurlo A, Foa P, Sala M, Maiolo A T
Istituto di Scienze Mediche, Padiglione Granelli, Università degli Studi, Milan, Italy.
Tumori. 1993 Aug 31;79(4):278-9. doi: 10.1177/030089169307900411.
The incidence of secondary malignancies following chemotherapy is progressively increasing, mostly due to prolonged survival of patients treated for primary cancer. So far, only 3 cases of solid cancer following busulphan administration have been reported. We describe the case of a patient who developed a renal cancer after 4 years of busulphan treatment for chronic myeloid leukemia. Immunosuppression rather than mutagenesis seems to be responsible for the emergence of second solid cancers in patients receiving busulphan.
化疗后继发恶性肿瘤的发生率正在逐渐上升，这主要归因于接受原发性癌症治疗患者的生存期延长。到目前为止，仅有3例使用白消安后发生实体癌的病例报道。我们描述了1例在接受白消安治疗慢性粒细胞白血病4年后发生肾癌的患者。接受白消安治疗的患者出现第二种实体癌似乎是免疫抑制而非诱变作用所致。
